EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseUmbrella ReviewOpen Access · CC BY 4.0

Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses

Yunfang Wang, Jianguo Xu, Yafei Xie, Dan Zhou, Mingyue Guo, Yu Qin, Kang Yi, Jinhui Tian, Tao You

Frontiers in Pharmacology · 05.12.2024 · 15

DOI: 10.3389/fphar.2024.1479983 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.12.2024. Verfasst von Yunfang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, China. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab therapy for HER2-positive cancers is associated with cardiotoxicity. This umbrella review synthesizes evidence from systematic reviews and meta-analyses on cardioprotective interventions during trastuzumab treatment.

Methods

A comprehensive search was conducted in PubMed, Embase, Cochrane Library, and Web of Science. Systematic reviews and meta-analyses examining cardioprotective interventions in patients receiving trastuzumab were included. The methodological quality was assessed using the AMSTAR-2 tool. Data on cardiac events, treatment interruptions, left ventricular ejection fraction (LVEF) changes, and exercise interventions were synthesized.

Results

Ten systematic reviews met the inclusion criteria. Statins demonstrated the strongest cardioprotective effect (RR = 0.47, 95% CI: 0.26–0.84), potentially preventing more than half of cardiac events during trastuzumab therapy, followed by beta-blockers (RR = 0.61, 95% CI: 0.39–0.93). Beta-blockers and ACEIs effectively reduced treatment interruptions, enabling approximately 40% more patients to maintain treatment continuity (RR = 0.63, 95% CI: 0.47–0.86). Among non-pharmacological interventions, structured exercise programs showed significant benefits in preserving cardiac function, demonstrating meaningful improvements in resting LVEF (WMD = −3.27%, 95% CI: −5.86 to −0.68).

Discussion

This review demonstrates that cardioprotective interventions, particularly statins and beta-blockers, significantly reduce the risk of cardiac complications during trastuzumab therapy. The positive impact on cardiac events and treatment interruptions suggests these interventions may enhance overall treatment efficacy by allowing more patients to complete their prescribed course.

Conclusion

Evidence strongly supports the systematic implementation of cardioprotective strategies in clinical practice, particularly statins and beta-blockers, as part of routine care protocols for patients receiving trastuzumab therapy. These interventions demonstrate significant potential in preventing cardiac complications and maintaining treatment continuity. Further research should focus on optimizing personalized approaches and evaluating long-term outcomes.

Schlagwörter

Stichwörter der Autor:innen

cardioprotective strategiescardiotoxicitymeta-analysistrastuzumabumbrella review

Autor:innen und Institutionen

  • Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, China.
  • Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  • Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Gastroenterology and Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Obstetrics, Xiangya Hospital Central South University, Changsha, China.
  • Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China.

Zitieren

APA

Wang, Y., Xu, J., Xie, Y., Zhou, D., Guo, M., Qin, Y., Yi, K., Tian, J., & You, T. (2024). Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1479983

Vancouver

Wang Y, Xu J, Xie Y, Zhou D, Guo M, Qin Y, et al. Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1479983

BibTeX
@article{Wang2024,
  author = {Wang, Yunfang and Xu, Jianguo and Xie, Yafei and Zhou, Dan and Guo, Mingyue and Qin, Yu and Yi, Kang and Tian, Jinhui and You, Tao},
  title = {Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1479983}
}
Kostenlos starten →